SLC5A2 and type 2 diabetes mellitus: Evidence has dramatically increased over the past several years based on recent studies, including the EMPAREG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in T2D Patients-Remove Excess Glucose) and the CANVAS (Canagliflozin Cardiovascular Assessment Study) Program (comprising the CANVAS and CANVAS-R trials) have demonstrated significant reductions in major adverse cardiac events (MACE) in patients randomized to receive SGLT2 inhibitor therapy compared with placebo [3, 4].